Dr. Reddy's Laboratories500124Pharmaceuticals
Citi upgraded Dr. Reddy's Laboratories to buy from sell, raising target price to Rs 1450
- New target price
- Rs 1450
- Old target price
- Rs 1040
- Incremental revenue estimate
- 350 to 400 million dollars
Heard on Live TV News Channel between 15:42:25 - 15:43:40 IST.
- Citi upgraded stock to buy from sell
- Target price raised to Rs 1450 from Rs 1040
- Sees catalysts including potential US launch of Abatacept and resumption of Semaglutide supplies in Canada
- Estimates $350-400 million incremental revenue over FY27-FY29
- Expects improving growth across India, emerging markets and Europe to drive favourable business mix
Also from Dr. Reddy's Laboratories
Dr Reddy's was among the top Nifty gainers after a double upgrade from Citi
29 Sep 2026
Dr Reddy was among the top gainers on the Nifty after a double upgrade from Citi
29 Sep 2026
Analyst recommended buying Dr. Reddy's as stock tests its 200-day moving average with strong volumes
29 Sep 2026
Source: Live TV News Channel · 29 Sep 2026
The call above is Citi's, reported here as they made it. Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.